Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Deguchi, H.
  • Fernandez, J. A.
  • Pabinger, I.
  • Heit, J. A.
  • Griffin, John

publication date

  • April 2001

journal

  • Blood  Journal

abstract

  • To assess the relationship between venous thrombosis and plasma glucosylceramide (GlcCer) or phosphatidylethanolamine (PE), plasma levels of GlcCer and PE were determined for 70 venous thrombosis patients referred for evaluation and 70 healthy blood donors. The mean GlcCer level, but not the PE level, was lower in patients versus controls (4.9 vs 6.5 microg/mL [P =.0007] and 66 vs 71 microg/mL [P =.48], respectively). As a measure of relative risk, the odds ratio for deep vein thrombosis in subjects with GlcCer levels below the 10th percentile of controls was 5.7 (95% CI, 2.3-14). To assess the influence of glycolipids on anticoagulant response to activated protein C (APC):protein S in modified prothrombin time assays, the effects of depleting endogenous plasma GlcCer by glucocerebrosidase treatment or of adding exogenous purified GlcCer or other neutral glycolipids to plasma were tested. Glucocerebrosidase treatment reduced plasma sensitivity to APC:protein S in parallel with GlcCer reduction. Exogenously added GlcCer and the homologous Glc-containing globotriaosylceramide (Gb3Cer), but not galactosylceramide, dose-dependently prolonged clotting times of normal plasma in the presence, but not absence, of APC:protein S, which suggests that GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. These results suggest that the neutral glycolipids GlcCer and Gb3Cer may directly contribute to the anticoagulant activity of the protein C pathway and that deficiency of plasma GlcCer may be a risk factor for venous thrombosis. (Blood. 2001;97:1907-1914)

subject areas

  • Activated Protein C Resistance
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Coagulation
  • Chromatography, High Pressure Liquid
  • Comorbidity
  • Contraceptives, Oral, Hormonal
  • European Continental Ancestry Group
  • Factor Va
  • Female
  • Galactosylceramides
  • Glucosylceramidase
  • Glucosylceramides
  • Humans
  • Male
  • Middle Aged
  • Neoplasms
  • Odds Ratio
  • Phosphatidylethanolamines
  • Postoperative Complications
  • Protein C
  • Protein S
  • Pulmonary Embolism
  • Risk
  • Thrombophilia
  • Trihexosylceramides
  • Venous Thrombosis
  • Wounds and Injuries
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0006-4971

Digital Object Identifier (DOI)

  • 10.1182/blood.V97.7.1907

PubMed ID

  • 11264150
scroll to property group menus

Additional Document Info

start page

  • 1907

end page

  • 1914

volume

  • 97

issue

  • 7

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support